TargetAldo-keto reductase family 1 member C1(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 4nMAssay Description:Inhibition of human recombinant 20-alpha HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C1(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Inhibition of human recombinant 20-alpha HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C2(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 82nMAssay Description:Inhibition of human recombinant type 3 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C2(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 87nMAssay Description:Inhibition of human recombinant type 3 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C1(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 140nMAssay Description:Inhibition of human recombinant 20-alpha HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C2(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 1.97E+3nMAssay Description:Inhibition of human recombinant type 3 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C3(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 4.20E+3nMAssay Description:Inhibition of human recombinant type 2 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C4(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 1.82E+4nMAssay Description:Inhibition of human recombinant type 1 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C3(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 2.10E+4nMAssay Description:Inhibition of human recombinant type 2 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C3(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 2.30E+4nMAssay Description:Inhibition of human recombinant type 2 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetAldo-keto reductase family 1 member C4(Homo sapiens (Human))
Monash University (Parkville Campus)
Curated by ChEMBL
Monash University (Parkville Campus)
Curated by ChEMBL
Affinity DataKi: 4.57E+4nMAssay Description:Inhibition of human recombinant type 1 3-alpha-HSD expressed in Escherichia coli JM109More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:Fluorescently-labeled inhibitor probe was synthesized and tagged with BODIPY FL (Example 46). Cbl-b displacement assays were performed in a 384-well ...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair